Artificial intelligence-driven pharmacovigilance analysis of polypharmacy and adverse events in breast cancer survivors treated with antidepressants

Certain polypharmacy regimens with antidepressants in specific breast cancer survivor subgroups may lead to complex safety signals. Personalized risk evaluation and vigilant medication safety strategies are crucial for these distinct, non-representative patients.